Mounjaro®
Starting from £179.99/mo
Start journey Learn moreAt 10 mg, Mounjaro (tirzepatide) is the fourth rung of a six-strength titration schedule that begins at 2.5 mg and climbs in 4-weekly steps. Most people reach 10 mg around month four or five of treatment, and for many it becomes their maintenance dose. It is a prescription-only medicine; a GPhC-registered prescriber decides whether you are clinically ready to move to this strength before it is dispensed.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Mounjaro is not prescribed at 10 mg from the start. The licensed schedule requires patients to spend at least four weeks at each preceding strength before a prescriber considers moving them up. That means a minimum of roughly 12 weeks on 2.5, 5 and 7.5 mg before 10 mg becomes relevant. The full Mounjaro strength schedule is worth reading if you want to understand where each dose sits in the overall plan.
The reason for this gradual approach is practical. Tirzepatide slows gastric emptying and acts on appetite-regulating hormones in the gut and brain. Going too fast risks compounding nausea, vomiting and other gastrointestinal effects that the step-up structure is specifically designed to flatten. By the time most people reach 10 mg their system has had months to settle, and many find this dose considerably more comfortable than the earlier weeks felt.
If you have needed more time at an earlier strength because of side effects, that is not a problem. The prescriber's role is to match the pace to you, not to a calendar. For context on what the move up from the previous strength looks like, the 5 mg Mounjaro page covers that earlier transition in detail.
Mounjaro's dual mechanism activates both GIP and GLP-1 receptors, making it the only licensed weight-loss medicine in the UK to work on two gut-hormone pathways simultaneously. At 10 mg the weekly dose is high enough that most people experience a pronounced reduction in appetite and a clear slowing of how quickly the stomach empties after eating. Meals feel more satisfying for longer, spontaneous snacking tends to fall away, and portion sizes often decrease without deliberate effort.
The NHS's tirzepatide medicine guide confirms that common side effects remain GI-led at this dose: nausea, constipation, diarrhoea, indigestion and, for some, belching or fatigue. These effects are typically most noticeable in the first week or two after a dose increase, then settle. If you are moving up from 7.5 mg, the dose-change considerations page has useful context on what the step-up period tends to feel like.
One practical note that patients at this stage often find reassuring: the pen itself does not change. Each Mounjaro KwikPen delivers four weekly doses and is used in the same way regardless of strength. Injection sites rotate between abdomen, thigh and upper arm; the technique stays consistent across the whole schedule.
The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults and followed them for 72 weeks. Participants on the 10 mg dose achieved average weight reductions that were clinically significant, though the headline figures most often quoted — around 20–21% — reflect the 15 mg arm. The 10 mg results were strong and statistically meaningful in their own right. NICE's appraisal of tirzepatide, TA1026, published in December 2024, draws on this evidence base when recommending tirzepatide as a cost-effective option for eligible adults.
For many people, 10 mg turns out to be the dose at which they stay. Not everyone needs or tolerates 12.5 or 15 mg, and a prescriber may recommend remaining at 10 mg if progress is steady and side effects are manageable. The weight-loss outcomes at 10 mg page goes into more detail on the clinical picture at this specific strength.
It is worth knowing that if you and your prescriber later decide a higher dose is appropriate, that decision rests on evidence of how you are responding, not on a default assumption that more is always better. Equally, the option to reduce a dose if needed is always on the table. Our page on decreasing your Mounjaro dose covers that question for anyone considering stepping back.
Because Mounjaro is a prescription-only medicine, reaching the 10 mg strength requires an ongoing clinical relationship, not a one-time assessment. Each dose increase is a fresh decision. At nume, when you request a repeat or an uplift, a GPhC-registered prescriber reads through your notes and progress the same day, not a piece of software, not a queue that clears next week.
The 10 mg Mounjaro pen page explains the dispensing and delivery side of things. On the cost side, the Mounjaro price page covers what private treatment typically costs and what a legitimate price includes. Orders placed before 12pm on a weekday are dispatched the same day once clinically approved and arrive the next working day via DPD, in plain unbranded packaging. For anyone looking at their broader options, the weight-loss treatment overview puts Mounjaro in the context of all available approaches.
If you think you might be approaching the 10 mg step, or if you are already there and have questions about what comes next, a good starting point is a free consultation with our team. A prescriber will review where you are in the schedule and whether the timing is right. You can start your free consultation here.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.